FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, in particular ophthalmology. Eye drops have a formulation as follows (g/l): timolol maleate (timolol basis) 1.0-6.0; disodium hydrogen phosphate 5.5-16.5; sodium dihydrogen phosphate 0.8-1.5; sodium chloride 2.0-6.0; ethylenediaminetetraacetatic acid disodium salt 0.1-0.5; benzalkonium chloride 0.03-0.1; polyvinylpyrrolidone 1-100, hydroxypropyl methylcellulose 1.0-5.0, water for injections - to 1 l. The viscosity values range within 5 to 20 mPa·s.
EFFECT: invention provides higher viscosity of the eye drops thereby enabling drug prolongation, as well as promotes cornea moistening and causes no irritant action on eye tissues, has long manufacturing and storage stability of the properties.
1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EYE DROPS | 2010 |
|
RU2431470C1 |
| OCULAR DROPS WITH REPARATIVE AND ANTI-GLAUCOMA ACTION | 2005 |
|
RU2295331C2 |
| CONTACT LENS CARE SOLUTION | 2020 |
|
RU2755298C1 |
| EYE DROPS FOR TREATING GLAUCOMA | 2002 |
|
RU2223099C1 |
| PHARMACEUTICAL ANTIGLAUCOMA COMPOSITION | 2009 |
|
RU2402316C2 |
| DROPS FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA, AND METHOD FOR PREPARING SAID DROPS | 1995 |
|
RU2099049C1 |
| OPHTHALMIC COMPOSITIONS CONTAINING PROSTAMIDE RELEASING NITROGEN OXIDE | 2019 |
|
RU2781022C2 |
| COMPOSITION OF AQUEOUS SOLUTION OF RECOMBINANT HUMAN INTERFERON ALPHA-2 FOR RECTAL ADMINISTRATION | 2014 |
|
RU2564951C1 |
| DRUG PREPARATION FOR TREATING CATARACT AND METHOD FOR PREPARING IT (VERSIONS) | 2012 |
|
RU2536958C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING EYE DISEASES RELATED TO EYE TISSUE METABOLIC DISEASE AND INFLAMMATORY EYE TISSUE INJURY | 2013 |
|
RU2521337C1 |
